Hrvoje Gasparovic (Department of Cardiac Surgery, University Hospital Center Zagreb, Zagreb, Croatia) and others write in The American Journal of Cardiology that the combination of aspirin and clopidogrel (or dual antiplatelet therapy) does not significantly reduce the risk of adverse events in aspirin-resistant patients who have undergone coronary artery bypass grafting (CABG) compared with aspirin monotherapy.
Edwards Lifesciences announced the successful completion of the first three human implants of its Fortis mitral transcatheter heart valve, which were performed in February and March by the Heart Team at St. Thomas’ Hospital in London, UK.
Transcatheter Technologies, a medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity—announced that its chief executive officer, Wolfgang Goetz, was awarded top prize for “best business pitch” in the 4th annual “German Venture Day” organised by Private Equity Forum NRW.
Medtronic announced that the European Patent Office has invalidated, in its entirety, the Edwards Lifesciences EP2055266 Spenser patent which was the basis for the August 26, 2013 injunction prohibiting sales of the CoreValve System in Germany.
On-X Life Technologies announced that it will launch its European marketing campaign for the On-X Plus 1.5 aortic heart valve in concert with its Great Britain distributor Vascutek at the Annual Meeting & Cardiothoracic Forum of the Society for Cardiothoracic Surgery in Great Britain & Ireland, March 10-12, Edinburgh, Scotland.
Micell Technologies announced that the long-term clinical outcomes from the DESSOLVE I and II clinical trials recently were presented at the Cardiovascular Research Technologies (CRT) Conference held in Washington, DC, February 22 - 25. The data presentation, “MiStent SES Clinical Program: DESSOLVE I and II Trials 2-Year Follow-up” was delivered by Alexandra Lansky, director, Interventional Cardiovascular Research and Angiography Core Laboratory Services with the Yale University School of Medicine, New Haven, USA.
GE Healthcare announced results from an independent study, which showed that use of isosmolar contrast agent Visipaque 320 (iodixanol 320mg I/ml) provides better image quality of coronary stents during multi-detector CT coronary angiography (MDCT-CA) than use of Iomeron 400 (iomeprol 400mg l/ml) when injected at the same flow rate (5.0 ml/s) and volume (80ml). Patients injected with Visipaque at 5.0 ml/s also experienced less heat sensation, fewer premature heart beats and their overall heart rate (HR) was less affected during scanning. The data were published online in Journal of Cardiovascular Computed Tomography.
Highlights of the American Heart Association (AHA) Scientific Sessions 2013, held in Dallas, Texas, USA, last November included success with a fourth new oral anticoagulant in patients with atrial fibrillation, and some benefit with spironolactone for heart failure patients with preserved left ventricular function, a group for whom no treatment is currently available.
In this new regular series ‘ECGs for the fainthearted’ Dr Heather Wetherell will be interpreting ECGs in a non-threatening and simple way. Confident interpretation of ECGs is fast becoming a dying art form. What’s more, it’s an art form that any good scientist can enjoy! ECGs are open to interpretation. The fun lies in solving the puzzle.
Volcano Corporation has announced US Food and Drug Administration (FDA) clearance of its proprietary instant wave-Free Ratio (iFR) Modality and immediate commencement of US limited market release.
On-X Life Technologies announced that it has assembled its European sales force at a training symposium in Barcelona ahead of launching its international marketing campaign for the On-X Plus 1.5 aortic heart valve.
CeloNova BioSciences announced that the US Food and Drug Administration (FDA) has granted approval to start an investigative device exemption (IDE) trial for its Cobra PzF coronary stent system.
Transcatheter Technologies announced the successful six-month follow-up results for a pilot study of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ transcatheter aortic valve implantation (TAVI) system.
Neovasc Inc announced that its Neovasc Reducer product for refractory angina was featured in a “live case” broadcast at the 10th Annual Congress of Update in Cardiology and Cardiovascular Surgery held in Antalya, Turkey. In the live case broadcast, Pierfrancesco Agostoni and Eric Duckers of the University Medical Center Utrecht in the Netherlands successfully implanted a Neovasc Reducer product in the coronary sinus of a 64-year old male patient suffering from refractory angina.
The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum announced a first-of-its-kind national campaign to help increase diversity in clinical trials.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos